What is the core difference between semaglutide and liraglutide?
Semaglutide and liraglutide belong to the same drug family: GLP-1 receptor agonists. GLP-1 is a hormone your gut releases after you eat; it tells your brain you are full and slows how fast your stomach empties. Both of these medicines are man-made copies of that hormone, and both work by turning that "I'm full" signal up and keeping it switched on. Neither adds a second receptor target the way the dual agonist tirzepatide does — they are both single-receptor GLP-1 drugs.
So if the mechanism is the same, what actually separates them? Three things. First, how often you take them: semaglutide is built to last about a week, so it is injected once weekly, while liraglutide is shorter-acting and is injected once a day. Second, age: liraglutide is the older molecule, approved years earlier, while semaglutide is the newer one designed to act longer and, in trials, more powerfully. Third, the size of the effect: in their respective obesity trials, semaglutide produced larger average weight loss than liraglutide.
Both are fully FDA-approved medicines that a clinician can prescribe today — this is not an approved-versus-investigational comparison. The choice between them is about dosing convenience, the strength of effect, and individual fit, not about whether one is a legitimate medicine.
Weekly vs daily: why does the dosing schedule differ?
The headline practical difference is frequency. Semaglutide is engineered to stay active in the body for roughly a week, which is why the injectable forms — Ozempic for type 2 diabetes and Wegovy for weight management — are taken just once a week. Liraglutide clears from the body much faster, so it has to be injected once every day; that is true of both its brands, Victoza for diabetes and Saxenda for weight management.
For many people, a once-weekly injection is simply easier to stick with than a daily one — fewer injections means fewer chances to forget a dose, and adherence is a real driver of how well any chronic medicine works. That convenience is one of the most-cited reasons semaglutide has become so widely used.
There is also a route difference that catches people out. Semaglutide is the only one of the two with an oral version: Rybelsus is a once-daily semaglutide tablet approved for type 2 diabetes. So while semaglutide is "the weekly one" as an injection, it is paradoxically taken daily when swallowed as Rybelsus. Liraglutide has no tablet form — it is injection-only.
Which produced more weight loss in clinical trials?
On weight, the trials point clearly in one direction — but it is important to understand they were separate studies, not a single head-to-head weight-loss contest. Semaglutide's flagship obesity trial, STEP 1, tested the 2.4 mg once-weekly dose (the Wegovy strength) in adults with overweight or obesity but without diabetes. Over 68 weeks, the semaglutide group lost a mean of about 14.9% of body weight, versus about 2.4% on placebo.
Liraglutide's comparable obesity trial, SCALE Obesity and Prediabetes, tested the 3.0 mg once-daily dose (the Saxenda strength) in a similar non-diabetic population. Over 56 weeks, the liraglutide group lost a mean of about 8.0% of body weight, versus about 2.6% on placebo.
Roughly 15% versus roughly 8% is a meaningful gap, and the responder rates tell the same story: in STEP 1, about 86% of participants lost at least 5% of their weight, about 69% lost at least 10%, and about 51% lost at least 15%; in SCALE, about 63% lost at least 5% and about 33% lost at least 10%. The caveat is real, though — different trials, different durations (68 vs 56 weeks), different dose strengths, and different populations, so this is a comparison by proxy, not a direct measurement of one drug against the other in the same room.
Has anyone compared them head-to-head?
Yes — but in diabetes, not in obesity, and at lower doses than the weight-loss versions. The SUSTAIN 10 trial is the cleanest direct comparison of the two molecules: it randomised adults with type 2 diabetes to once-weekly semaglutide 1.0 mg or once-daily liraglutide 1.2 mg over 30 weeks, with both added on top of oral diabetes drugs.
Semaglutide came out ahead on both endpoints. Average blood-sugar (HbA1c) fell by about 1.7 percentage points with semaglutide versus about 1.0 point with liraglutide, and average weight fell by about 5.8 kg with semaglutide versus about 1.9 kg with liraglutide. More participants on semaglutide also reached the blood-sugar and weight-loss targets the trial set.
Two things to keep in mind. First, this used the diabetes doses (1.0 mg semaglutide, 1.2 mg liraglutide), not the higher weight-management doses (2.4 mg semaglutide, 3.0 mg liraglutide), so it does not settle the obesity question directly. Second, the gastrointestinal side effects were somewhat more frequent with semaglutide in this trial. It is the best direct evidence we have that, dose for dose in diabetes, semaglutide tends to lower blood sugar and weight more than liraglutide.
How do they compare for type 2 diabetes?
Both drugs are approved type 2 diabetes treatments and both lower blood sugar effectively — that is their original indication. Liraglutide (as Victoza) arrived first, approved in 2010, and built a long real-world track record. Semaglutide (as Ozempic) followed in 2017 and, as the SUSTAIN 10 head-to-head showed, tends to deliver a somewhat larger HbA1c reduction at its diabetes dose.
Semaglutide also uniquely offers an oral route for diabetes: Rybelsus, a once-daily tablet, is an option for people who would rather not inject at all. Liraglutide has no equivalent pill. For a clinician choosing between them in diabetes, the trade-offs are roughly: semaglutide for a once-weekly schedule (or a daily pill) and generally larger glucose and weight effects, versus liraglutide as the longer-established daily injection with a deep safety history.
Neither of these is dosing advice. The actual choice — and the starting dose, titration pace, and how it fits alongside other diabetes medicines — is a decision for a prescribing clinician who knows your full history.
What does the heart-health evidence show?
A major reason these two drugs are valued beyond blood sugar is that both have dedicated cardiovascular-outcomes trials — large studies designed to test whether the drug reduces heart attacks, strokes, and cardiovascular death in people with type 2 diabetes at high risk. This is a meaningful similarity: not every diabetes drug has this kind of outcome data, and both of these do.
For liraglutide, the LEADER trial followed more than 9,000 people with type 2 diabetes and high cardiovascular risk. The combined rate of cardiovascular death, non-fatal heart attack, or non-fatal stroke (often called MACE) was lower with liraglutide than placebo — about 13.0% versus 14.9% — establishing a cardiovascular benefit.
For semaglutide, the SUSTAIN-6 trial tested the injectable form against placebo in a similar high-risk diabetes population. The same MACE composite occurred in about 6.6% on semaglutide versus 8.9% on placebo. Both trials used the diabetes doses and enrolled different populations, so the percentages are not directly comparable head-to-head — but the shared takeaway is that each drug has trial evidence of reducing cardiovascular events, which is part of why both are widely used.
How do the side effects compare?
Because they share the same mechanism, the side-effect profiles look very similar. The dominant adverse effects of both are gastrointestinal — nausea, diarrhea, vomiting, and constipation. These are dose-dependent, tend to be worst when starting or when the dose is stepped up, and usually ease as the body adapts. This is exactly why both drugs are started low and titrated up slowly rather than begun at the full dose.
There are a few nuances. In the SUSTAIN 10 head-to-head, gastrointestinal complaints were somewhat more common with semaglutide than liraglutide at the doses tested. Both carry the GLP-1 class warnings a clinician will review, including a boxed warning about thyroid C-cell tumours seen in rodents (the human relevance is uncertain), and both should be discussed in the context of personal and family medical history.
The honest summary is that the two have broadly overlapping tolerability, dominated by manageable, usually temporary stomach effects — and that any side effect that is severe, persistent, or worrying is a reason to contact a clinician rather than push through.
Which one fits whom?
Because both are approved and effective, the choice is genuinely individual, and it belongs with a clinician. That said, the trial and label differences sketch out the typical considerations. Semaglutide is often favoured where a once-weekly injection (or, for diabetes, a daily pill) suits the person better, and where the larger average weight-loss and glucose effects in trials are the priority.
Liraglutide can be the better fit in other situations: it is the longer-established molecule with a deep safety record, it is sometimes available when the newer drug is in short supply, and its daily, shorter-acting profile can be useful when a clinician wants to be able to adjust or stop the effect more quickly. Insurance coverage, cost, and which brand is indicated for the specific goal (diabetes versus weight management) all factor in too.
None of this is a recommendation of one drug over the other, and nothing here is medical advice. The right answer depends on your goals, your medical history, what your insurance covers, and your clinician's judgement — which is exactly the kind of decision these comparisons are meant to inform, not replace.
Tracking either GLP-1 on PeptidePanel
Whichever drug a clinician prescribes, the day-to-day work of staying on a GLP-1 is the same: take the dose on schedule (weekly for semaglutide injections, daily for liraglutide or Rybelsus), watch the biomarkers that matter (HbA1c, weight trend, lipids), and catch side effects early. That is easy to lose track of, especially while titrating up.
PeptidePanel is the neutral tracking layer for exactly that. It records the protocol your clinician sets, charts your bloodwork against reference ranges, and reminds you when a dose or a lab is due. It does not sell, source, or supply any medicine — it is a monitoring tool for a protocol that a qualified prescriber has already put you on.